Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus.
|
| Abstract |
Primary effusion lymphoma (PEL) is a recently recognized disease that occurs most often in immunosuppressed patients, either with human immunodeficiency virus (HIV) or in the posttransplantation setting, and it occasionally occurs in nonimmunosuppressed patients. Patients present with lymphomatous effusions in serous cavities--pleura, pericardium, or peritoneum--without any identifiable tumor mass. PEL rarely responds to systemic chemotherapy, and the prognosis is poor, with a median survival time of less than 6 months for most cohorts. A standard treatment for PEL has not yet been identified. We describe a patient with HIV-seronegative PEL who relapsed after combination chemotherapy and then underwent successful treatment with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). The treatment was well tolerated, and the patient has been in remission for 12 months after HDC and ASCT.
|
|---|---|
| Authors | Jong-Ho Won, Seung-Hyo Han, Sang-Byung Bae, Chan-Kyu Kim, Nam-Su Lee, Kyu-Taeg Lee, Sung-Kyu Park, Dae-Sik Hong, Dong-Wha Lee, Hee-Sook Park |
| Journal | International journal of hematology (Int J Hematol) Vol. 83 Issue 4 Pg. 328-30 (May 2006) ISSN: 0925-5710 [Print] Japan |
| PMID | 16757433 (Publication Type: Case Reports, Journal Article) |
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!